Table 1.

Baseline characteristics of included studies.

References	Start	Design	ICH Type	No. of Subjects	Mean age	Female	Prevalence of anemia	Mean of hemoglobin	ICH volume	Outcome definition	NIHSS score	Follow-up (Losses to follow-up, %)
Kumar et al. (9)	1999–2005	Pro.	Supra.	685	71.3	44.8%	25.84%	135.8 g/L	Anemia: 42.7 ml (IQR 1.0–167.0)	30-days mortality	NOA	1 month (1%)
									Non-anemia: 34.3 ml (IQR 1.0–159.0)
Diedler et al. (8)	2004–2004	Retro.	Supra.	196	67.1	33.7%	NOA	137 g/L	mRS 4-6: 13.6 ml (IQR 66.4)	mRS4-6	NOA	3 month (10%)
									mRS 2-3: 8.6 ml (IQR 24.0)
Kuramatsu et al. (10)	2006–2010	Pro.	Supra.& Infra.	435	69.7	45%	24.14%	130 g/L	Anemia: 48.6 ml (IQR 12.1-82.2) Non-anemia: 15.0 ml (IQR 4.8-40.6)	mRS	Anemia: 22(15–32)Non-anemia: 14(5–24)	12 month (0%)
Bussiere et al. (18)	2003–2008	Pro.	Supra.& Infra.	2389	68.0	46.3%	22.69%	138.0g/L	NOA	mRS4-6 and mortality	CNS Score	12 month (0%)
Chang et al. (19)	2008–2010	Retro.	Supra.& Infra.	109	59.8	45.9%	27.53%	110.9g/L	NOA	mRS	Anemia: 16(0–40)	NOA
											Non-anemia: 14(1–40)
Zeng et al. (20)	2007–2008	Pro.	Supra.& Infra.	2513	61.9	38.7%	19.30%	NOA	Anemia*: 14.71 ml (IQR 6.24–30.24)	mRS4-6 and mortality	Anemia: 10 (4–17)	12 month (8%)
											Non-anemia: 9 (3–16)
									Non-anemia*: 14.85 ml (IQR 6–29.4)
Barlas et al. (21)	2003–2015	Pro.	Supra.& Infra.	1001	77.8	52.4%	21.58%	NOA	NOA	mortality	NOA	12 month (?%)

Supra, supratentorial; Infra., infratentorial; Pro., prospective; Retro., retrospective;

^*, specifically for supratentorial ICH volume; mRS, modified Rankin Scale.